Pathologic Response to Preoperative Chemotherapy

LAUR Repository

Show simple item record

dc.contributor.author Blazer III, Dan
dc.contributor.author Kishi, Yoji
dc.contributor.author Maru, Dipen
dc.contributor.author Shin Chun, Yun
dc.contributor.author Overman, Micheal
dc.contributor.author Fogelman, David
dc.contributor.author Eng, Cathy
dc.contributor.author Chang, David
dc.contributor.author Wang, Huamin
dc.contributor.author Zorzi, Daria
dc.contributor.author Ribero, Dario
dc.contributor.author Ellis, Lee
dc.contributor.author Glover, Katrina
dc.contributor.author Wolff, Robert
dc.contributor.author Curley, Steven
dc.contributor.author Abdalla, Eddie
dc.contributor.author Vauthey, Nicolas
dc.date.accessioned 2015-11-16T12:43:44Z
dc.date.available 2015-11-16T12:43:44Z
dc.date.copyright 2008
dc.date.issued 2015-11-16
dc.identifier.issn 0732-183X en_US
dc.identifier.uri http://hdl.handle.net/10725/2584
dc.description.abstract Purpose The primary goal of this study was to evaluate whether pathologic response to chemotherapy predicts patient survival after preoperative chemotherapy and resection of colorectal liver metastases (CLM). The secondary goal of the study was to identify the clinical predictors of pathologic response. Patients and Methods A retrospective review was performed of 305 patients who underwent preoperative irinotecan- or oxaliplatin-based chemotherapy, followed by resection of CLM. Pathologic response was systematically evaluated and reported as the mean of the percentage of cancer cells remaining within each tumor. Univariate and multivariate analyses were performed to identify the predictors of pathologic response and survival. Results Cumulative 5-year overall survival rates by pathologic response status were as follows: 75% complete response (no residual cancer cells), 56% major response (1% to 49% residual cancer cells), and 33% minor response (≥ 50% residual cancer cells; complete v major response, P = .037; major v minor response, P = .028). Multivariate analysis revealed that only surgical margin status (P = .050; hazard ratio [HR], 1.77) and pathologic response (major response: P = .034; HR, 4.80; minor response: P = .007; HR, 6.93) were independent predictors of survival. Multivariate analysis of the predictors of pathologic response revealed that carcinoembryonic antigen level ≤ 5 ng/mL, tumor size ≤ 3 cm, and chemotherapy with fluoropyrimidine plus oxaliplatin and bevacizumab were independent predictors of pathologic response. Conclusion Pathologic response predicts survival after preoperative chemotherapy and resection of CLM. Degree of pathologic response represents a new outcome end point for prognosis after resection of CLM. en_US
dc.language.iso en en_US
dc.title Pathologic Response to Preoperative Chemotherapy en_US
dc.type Article en_US
dc.description.version Published en_US
dc.title.subtitle A New Outcome End Point After Resection of Hepatic Colorectal Metastases en_US
dc.author.school SOM en_US
dc.author.idnumber 201100945 en_US
dc.author.woa N/A en_US
dc.author.department N/A en_US
dc.description.embargo N/A en_US
dc.relation.journal Journal of Clinical Oncology en_US
dc.journal.volume 26 en_US
dc.journal.issue 33 en_US
dc.article.pages 5344-5351 en_US
dc.identifier.doi http://dx.doi.org/10.1200/JCO.2008.17.5299 en_US
dc.identifier.ctation Blazer, D. G., Kishi, Y., Maru, D. M., Kopetz, S., Chun, Y. S., Overman, M. J., ... & Vauthey, J. N. (2008). Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. Journal of Clinical Oncology, 26(33), 5344-5351. en_US
dc.author.email eddie.abdalla@lau.edu.lb
dc.identifier.url http://jco.ascopubs.org/content/26/33/5344.short

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account